The first and only anti-VEGF proven effective and safe for diabetic retinopathy (DR) with and without DME 1,13

Safety in DR

Select Safety in RISE & RIDE

OCULAR REACTIONS 1,8

SERIOUS NON-OCULAR REACTIONS 8

APTC, Antiplatelet Trialists' Collaboration; ATE, arterial thromboembolic event; MI, myocardial infarction; VEGF, vascular endothelial growth factor.

MOST COMMON NON-OCULAR REACTIONS 1

LUCENTIS 0.3 MG (N=250) VS SHAM (N=250):
Nasopharyngitis (12% vs 6%), anemia (11% vs 10%), nausea (10% vs 9%), and cough (9% vs 4%)

Resources
Resources for your patients.
LUCENTIS Direct
Simple, personalized ordering.
LUCENTIS Co-pay Card Program
Support for your patients with commercial insurance.
LUCENTIS Access Solutions
Genentech Access Solutions is your resource for access and reimbursement support services.